Literature DB >> 19893040

Feasibility of immunotherapy for lymphangioleiomyomatosis.

Michele Carbone1.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19893040      PMCID： PMC2789604          DOI： 10.2353/ajpath.2009.090900

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  21 in total

1.  CD4-veCD8-ve CD30+ve T cells are detectable in human lung transplant patients and their proportion of the lymphocyte population after in vitro stimulation with donor spleen cells correlates with preservation of lung physiology.

Authors:  K Polster; A Walker; J Fildes; G Entwistle; N Yonan; I V Hutchinson; C T Leonard
Journal:  Transplant Proc       Date:  2005-06       Impact factor: 1.066

2.  Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.

Authors:  Angelo M Taveira-DaSilva; Mario P Stylianou; Carolyn J Hedin; Olanda Hathaway; Joel Moss
Journal:  Chest       Date:  2004-12       Impact factor: 9.410

3.  Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism.

Authors:  Magdalena Karbowniczek; Aristotelis Astrinidis; Binaifer R Balsara; Joseph R Testa; James H Lium; Thomas V Colby; Francis X McCormack; Elizabeth Petri Henske
Journal:  Am J Respir Crit Care Med       Date:  2002-10-31       Impact factor: 21.405

4.  The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis.

Authors:  G D Strizheva; T Carsillo; W D Kruger; E J Sullivan; J H Ryu; E P Henske
Journal:  Am J Respir Crit Care Med       Date:  2001-01       Impact factor: 21.405

Review 5.  Melanosomal proteins as melanoma-specific immune targets.

Authors:  C Sakai; Y Kawakami; L W Law; M Furumura; V J Hearing
Journal:  Melanoma Res       Date:  1997-04       Impact factor: 3.599

6.  Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis.

Authors:  Xiaoning Zhe; Lucia Schuger
Journal:  J Histochem Cytochem       Date:  2004-12       Impact factor: 2.479

7.  When to suspect and how to diagnose pulmonary lymphangioleiomyomatosis.

Authors:  A Naalsund; B Johansen; A Foerster; A Kolbenstvedt
Journal:  Respirology       Date:  1996-09       Impact factor: 6.424

Review 8.  T cell receptor gene therapy for cancer.

Authors:  Thomas M Schmitt; Gunnar B Ragnarsson; Philip D Greenberg
Journal:  Hum Gene Ther       Date:  2009-11       Impact factor: 5.695

Review 9.  Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

Authors:  Pedro Romero; Danila Valmori; Mikael J Pittet; Alfred Zippelius; Donata Rimoldi; Frederic Lévy; Valérie Dutoit; Maha Ayyoub; Verena Rubio-Godoy; Olivier Michielin; Philippe Guillaume; Pascal Batard; Immanuel F Luescher; Ferdy Lejeune; Danielle Liénard; Nathalie Rufer; Pierre-Yves Dietrich; Daniel E Speiser; Jean-Charles Cerottini
Journal:  Immunol Rev       Date:  2002-10       Impact factor: 12.988

10.  MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development.

Authors:  Shaowei Li; Fumiko Takeuchi; Ji-an Wang; Christopher Fuller; Gustavo Pacheco-Rodriguez; Joel Moss; Thomas N Darling
Journal:  J Exp Med       Date:  2005-08-29       Impact factor: 14.307
View more
  2 in total

Review 1.  Optimizing treatments for lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Joel Moss
Journal:  Expert Rev Respir Med       Date:  2012-06       Impact factor: 3.772

Review 2.  The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis.

Authors:  Sean P Delaney; Lisa M Julian; William L Stanford
Journal:  Front Cell Dev Biol       Date:  2014-11-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.